PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Rating of "Moderate Buy" from Analysts

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fifteen research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $65.00.

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. cut their price target on shares of PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Citigroup upgraded shares of PTC Therapeutics from a "sell" rating to a "neutral" rating and dropped their price objective for the company from $50.00 to $40.00 in a research note on Wednesday, May 7th. Wells Fargo & Company upped their price objective on shares of PTC Therapeutics from $68.00 to $74.00 and gave the company an "overweight" rating in a research note on Tuesday, May 27th. Royal Bank Of Canada upped their price objective on shares of PTC Therapeutics from $57.00 to $58.00 and gave the company an "outperform" rating in a research note on Wednesday, May 7th. Finally, Wall Street Zen lowered shares of PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 16th.

Insider Transactions at PTC Therapeutics

In related news, CEO Matthew B. Klein sold 2,804 shares of the company's stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $48.74, for a total transaction of $136,666.96. Following the completion of the sale, the chief executive officer now directly owns 273,234 shares of the company's stock, valued at approximately $13,317,425.16. This represents a 1.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Lee Scott Golden sold 897 shares of the company's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $46.95, for a total transaction of $42,114.15. Following the sale, the executive vice president now directly owns 75,997 shares of the company's stock, valued at approximately $3,568,059.15. This represents a 1.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,513 shares of company stock worth $308,498 in the last 90 days. 5.50% of the stock is owned by insiders.

Institutional Trading of PTC Therapeutics

Large investors have recently modified their holdings of the company. Smartleaf Asset Management LLC boosted its holdings in shares of PTC Therapeutics by 78.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 270 shares during the period. Sterling Capital Management LLC boosted its holdings in PTC Therapeutics by 424.4% in the 4th quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 522 shares during the period. Quantbot Technologies LP boosted its holdings in PTC Therapeutics by 545.5% in the 1st quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 551 shares during the period. PNC Financial Services Group Inc. boosted its holdings in PTC Therapeutics by 84.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 320 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in PTC Therapeutics by 86.3% in the 1st quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 441 shares during the period.

PTC Therapeutics Price Performance

PTCT stock opened at $50.20 on Friday. PTC Therapeutics has a 52-week low of $28.72 and a 52-week high of $58.38. The company's 50 day simple moving average is $47.95 and its 200-day simple moving average is $48.21. The firm has a market capitalization of $3.98 billion, a P/E ratio of 7.71 and a beta of 0.51.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.85 by $9.19. PTC Therapeutics had a net margin of 33.56% and a negative return on equity of 78.56%. The business had revenue of $1.18 billion for the quarter, compared to analyst estimates of $437.16 million. During the same quarter in the previous year, the business earned ($1.20) earnings per share. The firm's revenue was down 9.6% compared to the same quarter last year. Sell-side analysts predict that PTC Therapeutics will post -4.52 EPS for the current fiscal year.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.